131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: The first case report in Thailand

Journal of the Medical Association of Thailand

Volumn 96, Issue 6, 2013, Pages 756-760

  Kositwattanarerk, Arpakorn ^a   Changmuang, Wirote ^a   Sangsuriyan, Jatupol ^b   Thongklam, Kittiphong ^a   Sritara, Chanika ^a   Utamakul, Chirawat ^a   Chamroonrat, Wichana ^a   Thamnirat, Kanungnij ^a   Anongpornyochkul, Yoch ^a   Chancharunee, Suporn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Thailand Institute of Nuclear Technology (Public Organization)   (Thailand)

Author keywords

131I rituximab; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

ANTIFUNGAL AGENT; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RITUXIMAB I 131; UNCLASSIFIED DRUG; 131I RITUXIMAB; 131I-RITUXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYDRONEPHROSIS; LUNG ASPERGILLOSIS; LYMPH NODE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; RECURRENT DISEASE; THAILAND;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RECURRENCE; THAILAND;

EID: 84878748312     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003; 18: 513-524.
2. Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 2003; 44: 67-76.
3. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10: 1696-1711.
4. Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/ CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2005; 32: 458-469.
5. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39 (8 Suppl): 14S-20S.
6. Dillman RO. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med 2006; 6: 1-12.
7. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
8. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391-398.
9. Hayslip J, Fenning R. Safe administration of iodine-131 tositumomab after repeated infusionrelated reactions to rituximab. Oncologist 2007; 12: 338-340.
10. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23: 712-729.
11. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
12. Becker W, Behr T. High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab. Ann Hematol 2001; 80 Suppl 3: B130-B131.
13. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 4418-4425.
14. Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol 2008; 19: 1629-1633.
15. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 2011; 117: 45-52.